Literature DB >> 20008253

Overview of gene therapy clinical progress including cancer treatment with gene-modified T cells.

Malcolm K Brenner1, Fatma V Okur.   

Abstract

It is now twenty years since the first legal gene transfer studies were approved, and there has been considerable disappointment in the slow rate of progress that followed the initial studies. Gradually, however, as the limitations of available vectors are acknowledged and overcome, and with advances in our understanding of the molecular and cell biology of genetic diseases and of cancer, unequivocal successes are now being reported. In this paper we describe the remaining major roadblocks to successful gene therapy and outline approaches to overcome them. We also illustrate how genetically modified immune system cells are already being used for the effective treatment of hematological and other malignancies, and how these approaches are being modified so that they can be effective in treating a broader range of malignancies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20008253      PMCID: PMC2929387          DOI: 10.1182/asheducation-2009.1.675

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  41 in total

1.  Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor.

Authors:  John Maher; Renier J Brentjens; Gertrude Gunset; Isabelle Rivière; Michel Sadelain
Journal:  Nat Biotechnol       Date:  2002-01       Impact factor: 54.908

2.  Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients.

Authors:  E Y Nikitina; J I Clark; J Van Beynen; S Chada; A K Virmani; D P Carbone; D I Gabrilovich
Journal:  Clin Cancer Res       Date:  2001-01       Impact factor: 12.531

3.  Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer.

Authors:  T Stanislawski; R H Voss; C Lotz; E Sadovnikova; R A Willemsen; J Kuball; T Ruppert; R L Bolhuis; C J Melief; C Huber; H J Stauss; M Theobald
Journal:  Nat Immunol       Date:  2001-10       Impact factor: 25.606

4.  Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity.

Authors:  Catherine M Bollard; Claudia Rössig; M Julia Calonge; M Helen Huls; Hans-Joachim Wagner; Joan Massague; Malcolm K Brenner; Helen E Heslop; Cliona M Rooney
Journal:  Blood       Date:  2002-05-01       Impact factor: 22.113

5.  Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain.

Authors:  Helene M Finney; Arne N Akbar; Alastair D G Lawson
Journal:  J Immunol       Date:  2004-01-01       Impact factor: 5.422

6.  Redirection of antileukemic reactivity of peripheral T lymphocytes using gene transfer of minor histocompatibility antigen HA-2-specific T-cell receptor complexes expressing a conserved alpha joining region.

Authors:  Mirjam H M Heemskerk; Manja Hoogeboom; Roelof A de Paus; Michel G D Kester; Menno A W G van der Hoorn; Els Goulmy; Roel Willemze; J H Frederik Falkenburg
Journal:  Blood       Date:  2003-07-17       Impact factor: 22.113

7.  LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1.

Authors:  S Hacein-Bey-Abina; C Von Kalle; M Schmidt; M P McCormack; N Wulffraat; P Leboulch; A Lim; C S Osborne; R Pawliuk; E Morillon; R Sorensen; A Forster; P Fraser; J I Cohen; G de Saint Basile; I Alexander; U Wintergerst; T Frebourg; A Aurias; D Stoppa-Lyonnet; S Romana; I Radford-Weiss; F Gross; F Valensi; E Delabesse; E Macintyre; F Sigaux; J Soulier; L E Leiva; M Wissler; C Prinz; T H Rabbitts; F Le Deist; A Fischer; M Cavazzana-Calvo
Journal:  Science       Date:  2003-10-17       Impact factor: 47.728

8.  Generation of minor histocompatibility antigen HA-1-specific cytotoxic T cells restricted by nonself HLA molecules: a potential strategy to treat relapsed leukemia after HLA-mismatched stem cell transplantation.

Authors:  Tuna Mutis; Els Blokland; Michel Kester; Ellen Schrama; Els Goulmy
Journal:  Blood       Date:  2002-07-15       Impact factor: 22.113

Review 9.  Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene/Ganciclovir system: fifteen years of application.

Authors:  C Fillat; M Carrió; A Cascante; B Sangro
Journal:  Curr Gene Ther       Date:  2003-02       Impact factor: 4.391

10.  Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7.

Authors:  Juan F Vera; Valentina Hoyos; Barbara Savoldo; Concetta Quintarelli; Greta M P Giordano Attianese; Ann M Leen; Hao Liu; Aaron E Foster; Helen E Heslop; Cliona M Rooney; Malcolm K Brenner; Gianpietro Dotti
Journal:  Mol Ther       Date:  2009-03-03       Impact factor: 11.454

View more
  4 in total

Review 1.  Exploiting T cells specific for human minor histocompatibility antigens for therapy of leukemia.

Authors:  Marie Bleakley; Stanley R Riddell
Journal:  Immunol Cell Biol       Date:  2011-02-08       Impact factor: 5.126

2.  Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors.

Authors:  Virna Marin; Irene Pizzitola; Valentina Agostoni; Greta Maria Paola Giordano Attianese; Helene Finney; Alastair Lawson; Martin Pule; Raphael Rousseau; Andrea Biondi; Ettore Biagi
Journal:  Haematologica       Date:  2010-08-16       Impact factor: 9.941

3.  STAT3 Decoy Oligodeoxynucleotides-Loaded Solid Lipid Nanoparticles Induce Cell Death and Inhibit Invasion in Ovarian Cancer Cells.

Authors:  Yanhui Ma; Xiaolei Zhang; Xiaoxuan Xu; Liang Shen; Yao Yao; Ziyan Yang; Peishu Liu
Journal:  PLoS One       Date:  2015-04-29       Impact factor: 3.240

4.  Therapeutic properties of a vector carrying the HSV thymidine kinase and GM-CSF genes and delivered as a complex with a cationic copolymer.

Authors:  Irina V Alekseenko; Eugene V Snezhkov; Igor P Chernov; Victor V Pleshkan; Victor K Potapov; Alexander V Sass; Galina S Monastyrskaya; Eugene P Kopantzev; Tatyana V Vinogradova; Yuri V Khramtsov; Alexey V Ulasov; Andrey A Rosenkranz; Alexander S Sobolev; Olga A Bezborodova; Anna D Plyutinskaya; Elena R Nemtsova; Raisa I Yakubovskaya; Eugene D Sverdlov
Journal:  J Transl Med       Date:  2015-03-04       Impact factor: 5.531

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.